From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.

Ten years ago, we started Helix with a bold hypothesis: that genomics would move from the margins of medicine to its core. We believe that understanding a patient’s DNA wouldn’t just be helpful, but that it would be foundational to all parts of medicine.

Today, that future is taking shape. The evidence base has advanced rapidly with hundreds of different use cases. And we’ve partnered with leading care delivery systems across the country to bring genomic insights into primary care, cardiology, oncology, and beyond. Along the way, we’ve taken a digital-first approach to core care delivery infrastructure that allows providers to act on genetic findings—not just once, but over a lifetime.

The next 10 years will make it more clear that genomics isn’t just about the “test” or point solution pilots -- rather it will be a part of the new infrastructure of care.

Precision medicine won’t scale unless we change how we think

The problem isn’t scientific readiness. It’s operational imagination.

Historically, genomics was treated like an “extra”, referred out, siloed, or reserved for edge cases. But the greatest impact comes when it's mainstreamed directly into frontline workflows. When clinicians of all specialties, not just geneticists, can use it confidently, and it’s as routine and seamless as ordering a cholesterol test. The next 10 years must be about normalizing genomics, not just advancing use cases.

Owning the foundation means owning the future

At Helix, we’ve seen what success looks like. It starts with internal champions, leaders who set a vision. It requires investment in education, integration, and impact measurement. And it demands long-term thinking: this isn’t a one-year ROI play. It’s a generational shift in how we deliver care.

Health systems that treat genomics as infrastructure, who commit to genomics as a core data capability broadly and integrating deeply will lead the next decade of medicine.

The systems that lead will align their incentive models and control future

Health systems sit at a crossroads. Those who act now will build a dataset that powers not just patient care, but AI, clinical trials, and innovation. Those who wait will find themselves locked out of the insights their peers are using to transform care.

This is about more than access to a test. It’s about building a learning health system, one where genomic data becomes a renewable resource. Where sequencing once enables years of insights. Where every patient interaction makes the system smarter.

We’re at an inflection point. Precision care is no longer a futuristic ideal, it’s a present-day imperative. Decisions in the next 2-3 years will define care delivery for the next 20.